Thermo Fisher Scientific Acquires The Binding Site Group

October 31, 2022

Thermo Fisher Scientific has entered into a definitive agreement to acquire The Binding Site Group from a shareholder group led by Nordic Capital for £2.25 billion (about $2.6 billion). The Binding Site, a Birmingham-based specialist in protein and blood-cancer diagnostics with more than 1,100 employees and ~10% annual revenue growth, will join Thermo Fisher's Specialty Diagnostics segment to expand its capabilities in cancer diagnostics and monitoring.

Targets
The Binding Site Group
Sellers
Shareholder group led by Nordic Capital
Industry
Medical Devices
Location
West Midlands, United Kingdom
Transaction Type
Buyout

Explore More

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.